Seeking to Gain an Edge in Nascent Synthetic Bio Market, Febit Sues Codon for Infringement

Febit’s chief scientific officer Peer Stähler said this week that the firm has invested heavily in developing its synthetic biology application since its inception eight years ago and that investors see it as one of the most potentially lucrative applications in the company’s broadening portfolio.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.